Glivec licence extension

The licence for Glivec (imatinib) has been extended to include its use as an adjuvant post-surgery treatment in patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who are at significant risk of the cancer returning after surgery.

The recommended dose of Glivec for this new indication is 400mg once daily. 

View Glivec drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

MIMS launches Respiratory and Allergy Learning workshops 2019

MIMS launches Respiratory and Allergy Learning workshops 2019

Join us for the MIMS Workshops Respiratory and Allergy...

Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Widespread false diagnosis of COPD is exposing patients to unnecessary medication risks, study suggests